ATH 0.00% 0.5¢ alterity therapeutics limited

Whats the Futur, page-3

  1. 2,788 Posts.
    lightbulb Created with Sketch. 970
    Cowanna,
    MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 16th November 2020: Alterity Therapeutics (ASX:
    ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced the allowance of a new
    composition of matter patent by the United States Patent and Trademark Office (USPTO). The new patent
    is the product of in-house discovery research and is central to Alterity’s next generation drug development
    portfolio focussed on neurodegenerative diseases.
    The patent, entitled “Compounds for and Methods of Treating Diseases” (Application No. 16/818,641),
    covers more than 150 novel pharmaceutical compositions that are designed to redistribute the labile
    iron implicated in Parkinson’s disease, Alzheimer’s disease and other neurodegenerative conditions. The
    patent, which was filed in March of 2020, underwent prioritized examination by the USPTO.

    We do not know anything about these 150 compositions but it is "central to Alterity's next generation drug development". So there are possibilities to find one drug after this PBT2 coming to the market most likely this year (?).
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.5¢
Change
0.000(0.00%)
Mkt cap ! $23.60M
Open High Low Value Volume
0.5¢ 0.5¢ 0.5¢ $5.25K 1.050M

Buyers (Bids)

No. Vol. Price($)
65 79358419 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 28661867 27
View Market Depth
Last trade - 10.00am 25/06/2024 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.